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Summary
Efektywnoœæ miejscowa leczenia jako wyzwanie w raku niedrobnoko-
mórkowym p³uca: czy jest to kluczowy problem?
Streszczenie
Rak p³uc stanowi w dalszym ci¹gu wyzwanie dla radioterapeutów, wymagaj¹c lepszego dostosowania leczenia celem zmniejszenia wysokie-
go odsetka miejscowych niepowodzeñ. Wiele prób jasno wykaza³o, ¿e lepszy miejscowy rodzaj leczenia wi¹¿e siê z lepszymi wskaŸnikami 
prze¿ycia. Ten rodzaj leczenia polega na ³¹czeniu chemioterapii, zmienionych schematów frakcjonowania dawek oraz na nowej technice 
podwy¿szania dawki. Wszystkie te metody, które zostan¹ dalej szczegó³owo omówione w niniejszej pracy zawdziêczaæ nale¿y postêpowi 
nauki.
S³owa kluczowe: rak p³uca, radioterapia.
Lung cancer remains a major challenge for radiation oncologists requiring a better treatment modality to overcome the high rate of local 
failures. Several trials have clearly demonstrated that a better local control is associated with a better survival. Those include combined 
approaches with chemotherapy, altered fractionation schedules and the new issue of dose escalation, which is now available due to the tech-
nical progress and will be discussed in detail.
Key words: lung cancer, radiotherapy.
Proceedings from the Conference "Current Achievements in Oncology" Poznañ, 6-8 November 2003
Praca prezentowana na konferencji "Wspó³czesne Osi¹gniêcia w Onkologii" Poznañ, 6-8 listopada 2003
Lung cancer remains a major problem for medical com- several reasons for these poor results, such as a suboptimal 
munity. Surgery remains the cornerstone of cure for early radiation technique, an inadequate total dose, or poor 
lung cancer. However only less than one third of patients staging procedure. Indeed, there is a well known 
qualify for surgical resection, usually with stage I to IIIa relationship between the tumour size and the dose required 
of the disease. Indeed, patients with a more extensive but to achieve local control. In head and neck cancers, doses 
still localized disease within the chest (some cases of stage in excess of 65 Gy are used to cure tumours of 3 cm
IIIa and mainly stage IIIb) and those unfit for surgical rese- in diameter, whereas in most series, lung cancer patients 
ction due to medical contraindication were often in the past were usually treated with doses below 65 Gy. Furthermore, 
treated with radiation aimed either at a cure or more often at patients referred to the radiation oncologist were found
palliation. The results even in the best series were quite to have quite large tumours e.g. in the series of Gouders
dismal with 5-year survival rates below 10%. Even in stage I et al., T2N0 their tumours varied from 3 to 10 cm, pointing 
disease, results were not very successful, and many local out the weakness of the current TNM classification. Several 
failures were recorded: in a series of 123 patients treated in approaches are under investigation to improve local control 
several west European centres, the 5 year local failure rates (a prerequisite for cure) and to reduce metastatic dissemi-
were 42% for T1 and 82% for T2 tumours [1]. There are nation.
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The first question is to see if a better loco regional treat-
ment may lead to a better overall survival. Two old trials 
conducted by the Radiation Therapy Oncology Group 
(RTOG) and the European Organization for Research and 
Treatment of Cancer (EORTC)  were able to demonstrate, 
within the frame work of a randomised trial, that some 
improvement in local control may translate into an overall 
survival benefit [2,3]. The former trial evaluated three 
different doses of 40, 50 and 60 Gy delivered with 2 Gy daily 
fractions. The local failure dropped from 58 % after 40 Gy
to 35% after 60 Gy, whereas 3-year survival rates rose from 
6% for 40 Gy to 15% after 60 Gy (2). The EORTC trial
in a three-arm study comparing, a split course radiation 
schedule without or with weekly or daily cisplatine yielded 
similar results. The better survival observed with the two 
combined approaches was only due to a better loco 
2regional control: the daily arm of cisplatine (6mg/m ) 
a concurrent approach followed by an adjuvant schedule), yielded a 2 year survival rate of 26% compared to 13%
the place of maintenance chemotherapy, the drugs to be for radiation alone [3]. 
associated with cisplatine or carboplatine, the drug admi-There are several ways to improve local control: com-
nistration (single or multiple administration), and, of course, bined treatments with chemotherapy and radiotherapy, alte-
the radiation technique itself. Incidentally, all those trials red radiation schedules and escalating the total dose. First, 
used radiation doses below 70 Gy and, in the Furuse trial, in the eighties, it was strongly believed that the best way
patients were treated with a split course schedule delivering of combining drugs and radiation was to start with drugs: 
56 Gy, which explained the low rate of severe esophagitis.among the theoretical advantages, induction chemothe-
In an attempt to improve radiation efficacy, classicalrapy may also improve the results of chest irradiation due
or accelerated hyperfractionated schedules have been to a better oxygenation of the tumour or to a possible 
developed to increase the biological dose and to overcome protection of normal tissue in case of response. Indeed,
the problem of repopulation. The well-known CHART sche-the Dillman trial observed some improvement in long-term 
dule (54 Gy delivered with 3 daily fractions of 1.5 Gy oversurvival after two cycles of cisplatine and vinblastine follo-
12 consecutive days including the weekend) was clearly wed by chest irradiation (60 Gy with daily 2 Gy fractions) [4]. 
superior to 60 Gy in 6 weeks with daily 2 Gy per fraction;Later, two large trials conducted in France, and that by
the survival benefit was due to the improvement in local con-the RTOG confirmed this result [5,6]. Nevertheless, the sur-
trol especially for squamous cell carcinoma [11]. The 3-year vival benefit was mainly due to a reduction in distant me-
survival rate rose from 11 to 21% in favour of the CHART, tastases and rather than to better loco regional control:
while the free local tumour progression survival ratesin the well designed French trial, the local control rate at one 
at 3 years were 9% after 60 Gy and 17% after the CHART year in the two arms was also below 20% [5].
schedule respectively. What was interesting to note wasA concurrent approach has become more popular over 
the impact of this better local control on the rate of distant the last decade. The main concern is certainly the increase 
metastases: the CHART yields a 9% reduction in distant in acute haematological and non-haematological toxicity, 
metastases at 3 years. Two other trials have comparedespecially esophagitis when combing radiation with cis-
a hyperfractionated schedule either conventional or acce-platine. Several trials have been published or presented du-
lerated to a conventional radiation schedule without sho-ring meetings. The Furuse, RTOG, GLOT and Czech trials
wing a significant difference, however in both studies,yielded very similar results in favour of a concurrent appro-
the experimental arm yielded a better survival. In the RTOG ach in contrast to the induction approach. The 2 year sur-
trial, 69.6 Gy delivered with two daily fractions of 1.2 Gy vival rates rose to 35% for the concurrent arm and to less 
yielded 2 and 3 year survival rates of 24 and 13% compared than 30% for the induction arm, but there is a price to pay 
to 19 and 6% for the daily 2 Gy schedule [6]. The HART with an increase in grade 3 esophagitis (Figure1) [7-10].
schedule of the ECOG delivered a dose of 57.6 Gy withIn the only fully published trial, Furuse reported a lower 
3 daily fractions over 2.5 weeks without a treatment during incidence of local relapse for the concurrent approach:
the weekends [12]. In this trial, patients had an induction 50 out of 156 patients versus 65 out of 158 for the induction 
chemotherapy with carboplatine and taxol and were arm [7]. Nevertheless, we are still waiting for the publication 
randomised between the HART and 64 Gy in daily 2 Gy of those different trials, as well as for a longer period of ob-
fractions. The 2 and 3-year survival rates were 44 and 23% servation. There are also many unsolved questions: the best 
for the HART and 30 and 14% for the conventional schedule sequence (induction followed by a concurrent approach or, 
Figure 1. Results of randomised trials comparing sequential radio-chemo-
therapy versus concurrent chemo radiotherapy: 2 Y survival rates and grade 
3 or more esophagitis.
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respectively. Most probably, both trials did not include a su- of 20 Gy. For small volumes, doses of 90 Gy or more were 
fficient member of patients to demonstrate a small but safely delivered but this was certainly not the case for larger 
an important benefit (the HART trial included only 112 pa- volumes: in the RTOG trial, they reached 77 Gy when
tients and the RTOG 301 patients in the two radiation arms). the V20 varied between 25 and 37% [17]. This is certainly
There is clear evidence of a direct relationship between the greatest paradigm of dose escalation: higher radiation 
dose and tumour control: increasing the total dose results doses are certainly more important for larger tumours but 
in a better local control and survival. In the already old trial the tolerance of normal tissues which is partially volume 
of the RTOG conducted in the seventies, the failure rate related does not allow such escalation. Margins are usually 
within the irradiated volume decreased from 58% after added to take into account tumour movements due
40 Gy to 35% after 60 Gy when the total dose increased from to the breathing. Different techniques are developed to limit 
40 to 60 Gy [2]. There is another important basic principle those margins: breathing holding devices (the radiation is 
of radiotherapy: the relation between the total dose and only performed when the patient keeps to a predefined 
the volume effect. This applies both to the tumour and measured deep inspiration), gating techniques (the irra-
to normal tissue. The radiation dose necessary to control diation is only performed during a predetermined part
a tumour increases with its size, volume or the amount of the respiratory cycle while the patient is free breathing) 
of cells present. In the Morita series including 149 patients and the tracking system (the radiation beam follows
treated for a stage I NSCLC with doses between 60 and the tumour displacement during the breathing cycle). 
65 Gy, the local failure rate at 5 years was 38% for tumours In the past, elective nodal irradiation (ENI) was common 
smaller than 3 cm and 68% for tumours larger than 5 cm practice to follow the classical philosophy of radiation onco-
[13]. In the series of Bradley including 207 patients, logy to cover the area at risk for nodal dissemination. This 
the gross tumour volume was the most predictive variable was also based on the observation of a very low rate of fai-
for overall and cause specific survival in a multivariate lure within a prophylactic irradiated nodal area. It was also
analysis [14]. In a large series of patients included in phase a time when the imaging modalities were certainly not as 
III trials including stage I to IIIb, the in-field local control was effective as they are today. In a recent review of more than 
below 20% after doses of 60 to 65 Gy delivered with daily 1000 patients included in different RTOG protocols, only
2 Gy fractions [5,11]. Consequently, dose escalation is a ve- an inadequate coverage of the ipsilateral hilum had a signi-
ry appealing approach to improve local control and survival ficant negative impact; this was not observed for the media-
for NSCLC. Nevertheless, in the past, dose escalation was stinum, the supraclavicular areas or the contralateral hilum 
mainly limited by the radiation-induced toxicity especially [18]. This is in contrast with a prior analysis performed
at the level of the lungs. This was well illustrated by large on a limited number of patients [19]. Furthermore, several 
randomised phase II RTOG trial escalating the total dose authors have reported a very low rate of failure within a nodal 
with two daily fractions of 1.2 Gy. The optimal total dose was area not irradiated regardless of the tumour stage: Senan 
69.6 Gy whereas a higher radiation dose (to 79.2 Gy) yiel- reported 12 in-field failures and no nodal failure in a series
ded lower survival rates [15]. This dose escalation is now of 50 patients with stage IIIa or b [20]. Rosenzweig et al. re-
possible due to technical advances in imaging (CT, PET), ported a 2-year elective nodal control of 91% in a series
treatment planning (3D reconstruction) and delivery of irra- of 171 patients treated using a 3D-CRT approach [21].
diation by linear accelerators (multileaf collimator, portal In the series of Bradley et al., ENI had no impact on the pat-
imaging). This has led to the introduction in daily practice tern of failure for stage I disease: 5 failures out of 22 patients 
of 3D conformal radiation therapy (3D-CRT) and intensity treated with ENI versus 2 out of 33 without ENI [25]. The cur-
modulated radiation therapy (IMRT). Studies have clearly rent philosophy is to focus on the known disease and limit 
demonstrated the feasibility of this approach and outlined the treatment to the GTV in an attempt to be able to escalate 
some of the key problems. the dose. Indeed, failure to control the GTV and distant 
There are several special issues to be discussed with metastases are overwhelming the role of prophylactic nodal 
the new approaches. The tolerance of a normal tissue, irradiation but this may cause other problems with better 
especially the lungs or the oesophagus in the case of a con- treatments.
current chemo radiotherapy schedule, is certainly one Furthermore, current imaging modalities allow us to bet-
of the limiting factors. 3D-CRT have helped to clarify ter define our GTV especially with the introduction of PET not 
the tolerance of the lungs and the amount of normal lung only for the tumour but also for the positive nodes. In a series 
volume which can be safely irradiated: in the experience of 73 patients, the treatment plan was based on a CT and
of Graham et al., no case of grade 3 pneumonitis was seen on a PET and then compared to the surgical findings: CT 
when less than 25% of the lung received more than 20 Gy; was right in 55 cases and PET in 65 [22]. Interestingly,
this rate rose to 23% when this volume was greater than 40% the PET errors were due to misinterpretation in 5 cases and 
[16]. Trials of dose escalation were based on the tolerance to a minimal disease in three cases. The new generation 
 of normal tissues, and patients were stratified according PET machine including a CT may allow avoiding this pro-
to the volume of the normal lung receiving doses in excess blem of matching PET and CT data.
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The IMRT is another interesting approach very successful trol, but they included small tumour (less than 6 cm) without 
for some indications such as head and neck or prostatic nodal spread (Table 1) [25-28]. Furthermore, some series 
cancers, making it possible either to spare normal tissues included lung cancer and metastatic disease, and the fol-
(the salivary glands) or to escalate the dose. In the case low-up was often very short. The treatment delivered doses 
of lung cancer, this seems to be more controversial partially between 40 and 60 Gy in 4 to 10 fractions. In Onimaru and 
due to the limited tolerance of the lungs. Grills et al have Nagata series, there was some suggestion of a dose
compared in a series of 18 patients 4 different treatment effect with local failures only seen at the low dose level (48 or 
techniques: intensity modulated radiation therapy, opti- 40 Gy) [27, 28]. Chest pain or oesophageal toxicity has 
mised 3D-CRT using multiple beam angles, 3D-CRT with been reported. This approach is of great interest but once 
2 to 3 beams, and a 2 fields radiation technique with elective again it is only a valid tool for very selected cases with small
nodal irradiation [23]. The use of 3D CRT with a limited num-  tumours, the so-called good candidate also for surgery. 
ber of beams offered possibility of reducing normal tissue Increasing the physical or biological dose will also open 
toxicity but does not make it possible to escalate the dose the door to new acute or late toxicity which were till now 
beyond our current limits in node positive patients. For node unknown or seldom reported such as bone toxicity, necrosis 
negatives, IMRT is not beneficial but may be useful for node within the lung or cardiac problems. Thus, those patients 
positives or for volumes close to the oesophagus. should be treated in according to a well-designed protocol 
Escalating the dose by using a conventional daily radia- including a careful follow-up procedure to detect unusual 
tion schedule will protract the treatment leading to lesser late effects. Last but not least, the current TNM is a very 
potential benefit of higher radiation dose due to an active weak tool for radiation oncologists to select the best treat-
repopulation. The data from the randomised trials of acce- ment for their patients. It is rather a surgical vision as the tu-
lerated hyperfractionated schedules and the negative im- mour size is only used to differentiate between a T1 and
pact of breaks during radiation suggest that the total treat- a T2. Indeed, there is some correlation between stage
ment time remains an important factor. There are several and gross tumour volume but this is not always the case.
ways to overcome the problem of repopulation in the case In the past, it has often been considered that superior sulcus 
of dose escalation: using two fractions per day, a concomi- tumour with a Pancoast syndrome had a better prognosis 
tant boost, increasing the fraction size during all the treat- but this was probably due to the size of the tumour [29]. 
ment or at the end. The radiotherapy group of the EORTC Probably the GTV should be the key factor as reported by 
has just started a phase I/II trial where patients are stratified Bradley in his series of 207 patients treated with a 3D-CRT 
according to the V20: there is a dose escalation keeping technique and doses ranging from 60 to 85 Gy [14].
the total time the same (6 weeks) for V20 smaller than 25% The International Association for the Study of Lung Cancer 
and for greater V20 by reducing progressively the treatment (IASLC) is currently collecting worldwide data to search
duration. In both cases, the daily doses will be greater than for some important prognostic factors to be proposed
the classical and mythical 2 Gy fractions. There are already for the next TNM revision. 
some data with larger fraction size and shorter treatment In conclusion, the data available clearly demonstrate
duration: Cheung et al. reported their experience in a series the need for better treatments for NSCLC, including 
of 36 stage I patients treated with 48 Gy in 12 fractions over radiation and chemotherapy. 3D-CRT is becoming a part
2.5 weeks without ENI (24). Some unusual toxicity was of the curative treatment of lung cancer as well as che-
observed: acute dermatitis and late subcutaneous fibrous, motherapy, either as an induction or a concurrent approach 
but some patients were treated with a Co60 unit. for well-selected patients. Dose escalation requires that
Stereotactic radiotherapy is another way to combine the volume to the GTV is restricted and it will be more po-
the precision of 3D-CRT and to avoid the problem of repo- ssible to apply to small tumours leading to the dilemma
pulation. Most series reported a very high rate of local con- of dose escalation: larger tumours require a higher radiation 
Table 1. Results of selected series of stereotactic radiotherapy for lung cancer.
Authors Patients Lung
Ca
Size
cm
Dose
Gy
Fractions CR Local
Prog.
Nodal
Failure
28
50
25
40
9
50
25
31
Lee (25)
Uematsu (26)
Onimaru (27)
Nagata (28)
1,2 - 4,5
0,8 - 5
< 6
< 4
30 - 40
50 - 60
48 - 60
40 - 48
3 - 4
5 - 10
8
4
1
3
5
1
8
2
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